Reviva Pharmaceuticals (NASDAQ: RVPH) experienced a significant shift in analyst sentiment as Wall Street Zen upgraded its rating from “sell” to “hold.” This change was noted in a report released on Saturday, indicating that analysts are reassessing the company’s potential.
Several other research firms have also weighed in on Reviva’s stock. Benchmark reduced its target price from $14.00 to $7.00 while maintaining a “speculative buy” rating in a note published on September 15. In contrast, Chardan Capital has taken a more optimistic stance, upgrading Reviva to a “strong buy” on November 19.
HC Wainwright reiterated a “buy” rating on December 23, setting a price target of $4.00. Meanwhile, D. Boral Capital also maintained a “buy” rating with a modest price target of $2.00. Notably, Weiss Ratings reaffirmed a “sell (e+)” rating on October 8. Currently, one analyst awards Reviva a “strong buy,” seven assign a “buy,” and one labels it as a “sell.”
According to data from MarketBeat.com, the consensus rating for Reviva Pharmaceuticals is “Moderate Buy,” with a projected average price target of $3.86.
Quarterly Performance and Analyst Projections
Reviva Pharmaceuticals announced its latest quarterly earnings results on November 13. The company reported earnings per share (EPS) of ($0.06), surpassing analysts’ expectations of ($0.11) by $0.05. Looking ahead, analysts anticipate that Reviva will report an EPS of ($0.97) for the current fiscal year.
Institutional Investments in Reviva
Recent activity among institutional investors indicates growing interest in Reviva Pharmaceuticals. 683 Capital Management LLC acquired a new position in the second quarter valued at approximately $381,000. Persistent Asset Partners Ltd increased its stake by 300.0% in the same period, now holding 641,174 shares worth $244,000.
Armistice Capital LLC also made a notable investment, purchasing a new stake valued at around $1,026,000. Millennium Management LLC expanded its holdings by 15.0% in the third quarter, bringing its total to 1,711,221 shares, valued at $631,000. Geode Capital Management LLC increased its position by 6.9%, now owning 448,202 shares worth $171,000.
Currently, institutional investors and hedge funds hold approximately 63.18% of Reviva’s stock, reflecting a growing confidence in the company’s future prospects.
About Reviva Pharmaceuticals
Founded in 2002 and headquartered in Coral Gables, Florida, Reviva Pharmaceuticals is a specialty pharmaceutical company. It focuses on the acquisition, development, and commercialization of prescription drug products in the United States and select international markets. The company specifically targets under-promoted, off-patent pharmaceuticals that can benefit from innovative dosage forms to enhance patient compliance and therapeutic outcomes.
Reviva’s core activities include identifying FDA-approved drug candidates and developing formulations to serve niche or underserved patient populations, such as those requiring pediatric or orphan indications. The company also supports regulatory filings to bring its products to market.
As Reviva Pharmaceuticals navigates the complex landscape of pharmaceutical development, its recent ratings and financial outlook will be closely monitored by investors and analysts alike.
